Thermo Fisher Scientific’s Post

We’re excited to share that we’ve completed the acquisition of Olink Proteomics. Olink provides targeted protein biomarker discovery and precision proteomics. Together we will further strengthen our commitment to accelerate discoveries and scientific breakthroughs through advanced proteomics solutions. This is an exciting step for Thermo Fisher as we continue to expand our next-generation life sciences and mass spectrometry offerings for research and precision medicine. We look forward to welcoming Olink colleagues into the organization! Learn more: https://bit.ly/4cToTX8

We’re excited to announce the expansion of our Basel, Switzerland, site where the introduction of innovative robotics and integrated solutions for clinical trials support will help the European pharmaceutical and #biotech industry meet critical needs in the drug development process and accelerate delivery of new therapies to the patients who need them most.

We’re excited to collaborate with the National Cancer Institute (NCI) on the myeloMATCH umbrella trial in an effort to help advance research in precision oncology. This groundbreaking program will fast-track acute myeloid leukemia patient enrollment in clinical trials informed by genomic insights provided by our next-day, sequencing technology. Accelerating this research provides hope for a future in which patients will have access to the right therapies based on their genomic profile and transform their cancer treatment journey. https://bit.ly/4f1iACO

We are honored to have been named to TIME’s inaugural list of the World’s Most Sustainable Companies of 2024. The recognition underscores our commitment to the environment and sustainable business practices which is deeply rooted in our Mission to enable our customers to make the world healthier, cleaner and safer. See our CSR report to learn more about how we are making progress toward our net-zero emissions goal: https://lnkd.in/gDekchAX

Earlier this month, our site in Monza, Italy celebrated the grand opening of our local Training Center & Aseptic Academy. It’s a cutting-edge space that leverages augmented and virtual reality (AR/VR) to provide colleagues working across our #Steriles manufacturing capabilities – from operations to quality – with the opportunity to train in both hands-on and simulated Good Manufacturing Practice (GMP) environments. Thermo Fisher Scientific leaders – including Executive Vice President and Chief Operating Officer Michel Lagarde, Drug Product President Simona Fugazza and Vice President and General Manager for Drug Product EU and APAC Alexandre Pasini – attended the event.

Improving the number of women and other underrepresented groups in clinical trials is essential for achieving health equity. Dr. Rose Blackburne, MD, MBA, President, Medical Science and Strategy, and Global Head of General Medicine and Women’s Health, kicks off the third season of our #ScienceWithATwist podcast to explain the critical need for diversity in clinical trials, the history behind it, and why it’s important to expand research related to women beyond reproductive health. To learn more about the challenges, solutions, and recent advancements in clinical trial recruitment efforts, listen to the full discussion: https://lnkd.in/gbyGJCwx

At Thermo Fisher Scientific, we're committed to supporting researchers in their mission to discover life-changing therapies. Approximately 350 million people worldwide suffer from rare diseases, most of which are genetic, and plasmid DNA plays a key role in the lab where researchers are solving for these diseases. To help accelerate the research and progress of these therapies and bring hope to patients worldwide, we’re excited to introduce the Thermo Scientific KingFisher PlasmidPro, the only fully automated plasmid purification system that aims to help scale and accelerate this vital research. https://lnkd.in/gt8TG4pi

We are celebrating 10 years of #renewableenergy at our site in Cork, Ireland! The site is home to our Active Pharmaceutical Ingredient (API) manufacturing facility and home to our very own wind turbine, which stands 100 meters tall with 50 meter blades. The turbine has generated more than 75,000 megawatt hours of #electricity – the equivalent of powering approximately 17,000 homes for a year. In 2023 alone, the wind turbine generated 19% of the site’s energy, helping the company make progress toward the goal of reaching net zero emissions. We remain committed to deliver #sustainable energy and reduce our #carbonfootprint. Learn more about this site: https://lnkd.in/gRqrEMid

We are excited to have announced the opening of a new clinical and commercial ultra-cold facility in the Netherlands designed to help accelerate the development of advanced therapies. The new current good manufacturing practice (cGMP) facility provides pharma and biopharma customers tailored, end-to-end support throughout the clinical supply chain for high-value therapies, including cell and gene therapies, biologics, antibodies, and vaccines. Additionally, the site is designed to use 15% solar power and operates completely gas-free. It also provides sustainable heating and cooling with eco-friendly electric heat pumps and uses ultramodern heat recovery technology. https://lnkd.in/eQ-7Kx-f